The Finalists

Lyfebulb-Helsinn
Innovation Summit &
Award In Oncology

Eleven innovators will compete at the Lyfebulb-Helsinn Investment Fund Innovation Summit for the first ever Lyfebulb-Helsinn Investment Fund Innovation Award, which will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative efforts and ideas to better manage cancer using drugs, medical devices, or consumer products, and healthcare information technologies


MARCH 26-27, 2018 | MONTE-CARLO BAY HOTEL & RESORT, MONACO

Deadline for applications is January 22, 2018 at 11:59pm EST

Applications Are Now Closed

The Award

One innovator will be awarded the first Lyfebulb-Helsinn Investment Fund Innovation Award in cancer treatment and cancer supportive care


lyfebulb helsinn 2018 - oncology awards

ABOUT THE AWARD

Monetary grants up to $25K will be awarded to the winners, as well as the opportunity for all finalists to be in a position to be better noticed by venture capital funds

BENEFITS OF THE LYFEBULB-HELSINN INVESTMENT FUND INNOVATION SUMMIT & AWARD

National and international recognition. The benefit for innovators of participating is
the visibility given to the selected 10 finalists, and the Winner in particular

Invitation to the Lyfebulb–Helsinn Innovation Summit 2018 in Monaco as one of 10 Finalists.
The Innovation Summit aims to link innovators with senior leadership from Lyfebulb and Helsinn in order
to spotlight innovators’ efforts and ideas, and provide professional discussion, direction, and inspiration.

The winner will be chosen on March 27, 2018 by a prestigious, international panel.

THE SUMMIT

At this Summit, 10 selected Innovators will compete for
monetary grants and be given the opportunity to be considered for a
possible investment by the Helsinn Investment Fund


ABOUT THE SUMMIT

 

MARCH 26-27, 2018 | MONTE-CARLO BAY HOTEL & RESORT, MONACO

Beyond presenting their innovative ventures to this group, the 10 finalists will also have a chance to interact and exchange ideas on how to advance further patient innovatorship in the cancer community, engage with Lyfebulb founders, Helsinn Investment Fund leadership, representatives from the patient community, key opinion leaders, and potential investors and compete for a monetary grant.

The Lyfebulb-Helsinn Investment Fund Innovation Summit stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features people who have created a product and a company based on issues encountered because of their personal experiences with a chronic illness.

Patient innovators have a unique ability to create a value-adding disease intervention beyond therapy. Our aim is to support patient-driven innovation and we are laser-focused on improving the quality of life for those living with cancer.

AWARD & JUDGING CRITERIA

The Award is open to innovators currently working on an
groundbreaking project, which can advance the prevention, management, or
care of cancer. The Award is open to innovators focused on the better
management of cancer using drugs, medical devices, or consumer
products, and healthcare information technologies.


WHAT ARE THE JUDGING CRITERIA?

The judging panel will look for evidence of:

  • How does the invention/product have the potential to improve the lives of people with cancer?
  • How is the product or service unique in the market (not an altered marketed product) and meets other demands as well?
  • Usage of innovative and effective technologies that are scalable
  • Ability to meet most of the healthcare challenges (e.g. funding, regulations, requirements for clinical testing, etc.)

The Jury

SUMMIT AGENDA

March 26, 2018: Morning
Arrival
March 26, 2018: Afternoon
Peer-to-peer meet-ups
March 26, 2018: Evening
Informal dinner
March 27, 2018: Morning
Plenary “pitch” session: presentations
March 27, 2018: Mid-Morning
Standing lunch for participants and jury
March 27, 2018: Afternoon
Afternoon workshops & Plenary session
March 27, 2018: Evening
Gala dinner & Award winner announcement


Driving Change

Lyfebulb

Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease.

Helsinn Investment Fund

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions

For more information, visit www.helsinninvestmentfund.com